OverviewSuggest Edit

Lupin is a USD 2.06 billion innovation led transnational pharmaceutical major producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment. Lupin is the 6th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2014, Lupin's Consolidated turnover and Profit after Tax were Rs. 120,600 million (USD 2.06 billion) and Rs. 18,364 million (USD 393 million) respectively.

HQMumbai, IN
Employee Ratings3.8

Latest Updates

Employees (est.) (May 2021)18,302
Job Openings11
Share Price (Jun 2021)₹1.2 K
Cybersecurity ratingDMore

Key People/Management at Lupin

Manju D Gupta

Manju D Gupta

Kamal K Sharma

Kamal K Sharma

Vice Chairman
Vinita Gupta

Vinita Gupta

Chief Executive Officer, Director
Ramesh Swaminathan

Ramesh Swaminathan

Executive Director, Global Chief Financial Officer & Head Corporate Affairs
Richard Zahn

Richard Zahn

Independent Director
Jon Stelzmiller

Jon Stelzmiller

President – Head of US Specialty Business
Show more

Lupin Office Locations

Lupin has offices in Mumbai, Ankleshwar, Aurangabad, Bhopal and in 11 other locations
Mumbai, IN (HQ)
Laxmi Towers BKC Road
Ankleshwar, IN
123, 1, GIDC, Ankleshwar GIDC
Aurangabad, IN
28, 1, MIDC Industrial Area, Chilkalthana
Bhopal, IN
Plot No 198-202, Ward Number 11, Hoshangabad Rd, Sector B, Nr, Mandideep
Boisar, IN
142, MIDC Rd, Tarapur M.I.D.C.
Dabhasa, IN
Block Street Number 21
Show all (18)

Lupin Financials and Metrics

Lupin Revenue

Market capitalization (11-Jun-2021)


Closing stock price (11-Jun-2021)

Lupin's current market capitalization is ₹557.9 b.
Show all financial metrics

Lupin Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Lupin Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset


out of 100

CSRHub logo

Lupin Online and Social Media Presence

Embed Graph

Lupin News and Updates

Lupin Receives U.S. FDA Warning Letter for Somerset Facility

Lupin Receives U.S. FDA Warning Letter for Somerset Facility

World Asthma Spacers Market Outlook 2021-2025, Featuring Cipla Limited, GlaxoSmithKline plc (GSK), Koninklijke Philips N.V., and Lupin Limited

DUBLIN, May 24, 2021 /PRNewswire/ -- The "Global Asthma Spacers Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering. The global asthma spacers market has increased at a significant CAGR during the years...

Eli Lilly inks pacts for Baricitinib with Sun Pharma, Cipla, Lupin for COVID-19 treatment in India

Baricitinib is currently registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs.

Sun Pharma, Lupin, Wockhardt, Aurobindo Shares Lead Health Care Rally As RBI Eases Lending

The S&P BSE Healthcare Index gained as much as 2.5%, the most in almost a month to trade just shy of its 52-week high.

Lupin Market to Reach $38.8 Billion by 2027

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 8. - Influencer Pool: 491. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies. Project Details…

Outlook on the Cephalosporin Global Market to 2026 - Players Include Allergan, GlaxoSmithKline and Lupin Among Others

Dublin, Feb. 23, 2021 (GLOBE NEWSWIRE) -- The "Cephalosporin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global cephalosporin market reached a value of US$ 17.46 Billion in 2020. Cephalospo…
Show more

Lupin Frequently Asked Questions

  • When was Lupin founded?

    Lupin was founded in 1968.

  • Who are Lupin key executives?

    Lupin's key executives are Manju D Gupta, Kamal K Sharma and Vinita Gupta.

  • How many employees does Lupin have?

    Lupin has 18,302 employees.

  • Who are Lupin competitors?

    Competitors of Lupin include Mablink Bioscience, Mito BioPharma and Patagonia Pharmaceuticals.

  • Where is Lupin headquarters?

    Lupin headquarters is located at Laxmi Towers BKC Road, Mumbai.

  • Where are Lupin offices?

    Lupin has offices in Mumbai, Ankleshwar, Aurangabad, Bhopal and in 11 other locations.

  • How many offices does Lupin have?

    Lupin has 18 offices.